{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T23:18:51Z","timestamp":1722813531917},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult acute lymphoblastic leukemia\/lymphoma (ALL\/LBL) is a rare and heterogeneous malignancy characterized by uncontrolled proliferation of B or T cell precursor cells. Here, we retrospectively analyzed the outcome of early autologous stem cell transplantation in standard-risk patients in first complete remission (<jats:italic>n<\/jats:italic>=24) and of allogeneic transplantation in high and highest risk, and relapsed\/refractory patients (<jats:italic>n<\/jats:italic>=35). The 10-year overall survival after autologous transplantation was 45%. The 10-year overall survival after allogeneic transplantation was 58%. The cumulative incidence of relapse was 29% after allogeneic and 67% after autologous transplantation. The cumulative incidence of non-relapse mortality was 0% after autologous and 12% after allogeneic transplantation. This retrospective single center analysis in a limited number of standard-risk patients clearly demonstrates that early autologous transplantation in first complete remission leads to an acceptable long-term outcome with a short overall treatment duration of less than 6\u00a0months compared with more than 2\u00a0years with conventional chemotherapy. More sensitive and standardized methods to detect minimal residual disease (MRD) will further help to identify those patients more accurately who are most likely to benefit from such a short and intensive treatment strategy (i.e., MRD negative standard-risk patients) or those who require early targeted therapy (e.g., blinatumomab) in case of MRD positivity. Early allogeneic transplantation results in long-term survival\/cure in nearly two-thirds of all high and highest risk, and relapsed\/refractory patients.<\/jats:p>","DOI":"10.1007\/s00277-020-04391-x","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T16:03:00Z","timestamp":1611676980000},"page":"809-816","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience"],"prefix":"10.1007","volume":"100","author":[{"given":"Normann","family":"Steiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hetzenauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rudzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Peschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nevinny-Stickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Nussbaumer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Loacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gunsilius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Nachbaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"issue":"suppl 5","key":"4391_CR1","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C et al (2016) Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v69\u2013v82","journal-title":"Ann Oncol"},{"issue":"6","key":"4391_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"S Giebel","year":"2019","unstructured":"Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, Cornelissen JJ, Doubek M, Esteve J, Fielding A, Foa R, Gorin NC, G\u00f6kbuget N, Hallb\u00f6\u00f6k H, Hoelzer D, Paravichnikova E, Ribera JM, Savani B, Rijneveld AW, Schmid C, Wartiovaara-Kautto U, Mohty M, Nagler A, Dombret H (2019) Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 54(6):798\u2013809","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4391_CR3","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R et al (2016) International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 101(12):1524\u20131533","journal-title":"Haematologica."},{"issue":"10230","key":"4391_CR4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M (2020) Acute lymphoblastic leukaemia. Lancet. 395(10230):1146\u20131162","journal-title":"Lancet."},{"issue":"4","key":"4391_CR5","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood. 111(4):1827\u20131833","journal-title":"Blood."},{"issue":"15","key":"4391_CR6","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.4103\/0366-6999.161365","volume":"128","author":"Z Ding","year":"2015","unstructured":"Ding Z, Han MZ, Chen SL, Ma QL, Wei JL, Pang AM, Zhang XY, Liang C, Yao JF, Cao YG, Feng SZ, Jiang EL (2015) Outcomes of adults with acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of pretransplantation minimal residual disease: analysis from a single center of China. Chin Med J 128(15):2065\u20132071","journal-title":"Chin Med J"},{"key":"4391_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2018.03.018","volume":"96","author":"S Giebel","year":"2018","unstructured":"Giebel S, Labopin M, Potter M, Poir\u00e9 X, Sengeloev H, Soci\u00e9 G, Huynh A, Afanasyev BV, Schanz U, Ringden O, Kalhs P, Beelen DW, Campos AM, Masszi T, Canaani J, Mohty M, Nagler A (2018) Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: an analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer 96:73\u201381","journal-title":"Eur J Cancer"},{"issue":"24","key":"4391_CR8","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880\u20133889","journal-title":"J Clin Oncol"},{"issue":"23","key":"4391_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540\u20131545","journal-title":"N Engl J Med"},{"issue":"3","key":"4391_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","volume":"13","author":"W Mills","year":"1995","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol 13(3):588\u2013595","journal-title":"J Clin Oncol"},{"issue":"1","key":"4391_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3324\/haematol.2012.063438","volume":"98","author":"PS Becker","year":"2013","unstructured":"Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH (2013) Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica. 98(1):114\u2013118","journal-title":"Haematologica."},{"key":"4391_CR12","unstructured":"Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am J Hematol. n\/a(n\/a)"},{"issue":"Suppl 1","key":"4391_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/bmt.2012.282","volume":"48","author":"S Iacobelli","year":"2013","unstructured":"Iacobelli S, Committee ES (2013) Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 48(Suppl 1):S1\u2013S37","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"4391_CR14","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lh\u00e9ritier V, Fiere D (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22(20):4075\u20134086","journal-title":"J Clin Oncol"},{"issue":"15","key":"4391_CR15","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"JM Ribera","year":"2014","unstructured":"Ribera JM, Oriol A, Morgades M, Montesinos P, Sarr\u00e0 J, Gonz\u00e1lez-Campos J, Brunet S, Tormo M, Fern\u00e1ndez-Abell\u00e1n P, Gu\u00e0rdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Berm\u00fadez A, Cladera A, Escoda L, Garc\u00eda-Boyero R, del Potro E, Bergua J, Amigo ML, Grande C, Rabu\u00f1al MJ, Hern\u00e1ndez-Rivas JM, Feliu E (2014) Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol 32(15):1595\u20131604","journal-title":"J Clin Oncol"},{"issue":"3","key":"4391_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2017","unstructured":"Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, Sobral da Costa E, Kotrov\u00e1 M, Novakova M, Sonneveld E, Buracchi C, Bonaccorso P, Oliveira E, te Marvelde JG, Szczepanski T, Lhermitte L, Hrusak O, Lecrevisse Q, Grigore GE, Fro\u0148kov\u00e1 E, Trka J, Br\u00fcggemann M, Orfao A, van Dongen J, van der Velden V, EuroFlow Consortium (2017) Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 129(3):347\u2013357","journal-title":"Blood."},{"issue":"23","key":"4391_CR17","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.V126.23.680.680","volume":"126","author":"N G\u00f6kbuget","year":"2015","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C et al (2015) Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive b-cell precursor acute lymphoblastic leukemia (ALL). Blood 126(23):680","journal-title":"Blood"},{"key":"4391_CR18","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C et al (2020) Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma:1\u20139","DOI":"10.1080\/10428194.2020.1780583"},{"issue":"14","key":"4391_CR19","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Br\u00fcggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 131(14):1522\u20131531","journal-title":"Blood."},{"issue":"3","key":"4391_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41409-019-0702-2","volume":"55","author":"AH Bazarbachi","year":"2020","unstructured":"Bazarbachi AH, Al Hamed R, Labopin M, Afanasyev B, Hamladji RM, Beelen D et al (2020) Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant 55(3):595\u2013602","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"4391_CR21","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1038\/bcj.2016.84","volume":"6","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H (2016) Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473","journal-title":"Blood Cancer J"},{"issue":"23","key":"4391_CR22","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1002\/cncr.32335","volume":"125","author":"EJ Jabbour","year":"2019","unstructured":"Jabbour EJ, G\u00f6kbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS (2019) Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 125(23):4181\u20134192","journal-title":"Cancer."},{"issue":"4","key":"4391_CR23","first-page":"1619","volume":"86","author":"M Attal","year":"1995","unstructured":"Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP et al (1995) Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group Blood 86(4):1619\u20131628","journal-title":"BGMT Group Blood"},{"issue":"10","key":"4391_CR24","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","volume":"104","author":"M Hunault","year":"2004","unstructured":"Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, B\u00e9n\u00e9 MC, Ifrah N, GOELAMS (Groupe Ouest-Est des Leuc\u00e9mies Airgu\u00ebs et Maladies du Sang) Group (2004) Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 104(10):3028\u20133037","journal-title":"Blood."},{"issue":"6","key":"4391_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1182\/blood-2008-07-168625","volume":"113","author":"JJ Cornelissen","year":"2009","unstructured":"Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC et al (2009) Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 113(6):1375\u20131382","journal-title":"Blood."},{"issue":"1","key":"4391_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, Beelen D, Browne P, Volin L, Kyrcz-Krzemien S, Yakoub-Agha I, Aljurf M, Wu D, Michallet M, Arnold R, Mohty M, Nagler A (2017) Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 102(1):139\u2013149","journal-title":"Haematologica."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-04391-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04391-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T12:28:20Z","timestamp":1670934500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-04391-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["4391"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04391-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of Innsbruck Medical University of Innsbruck in view of the retrospective nature of the study and all the procedures being performed were part of the routine care<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}